Lupin Ltd
Company Profile
Business description
Lupin Ltd is a transnational pharmaceutical company engaged in producing, developing, and marketing branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs). The Company has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, Gastro-Intestinal, Anti-Infectives and Nonsteroidal Anti-Inflammatory Drug therapy segments and the Anti-TB and Cephalosporins segments. It operates through two segments: Pharmaceuticals, which consists of producing, developing, and marketing pharmaceutical products, and Others, which consists of diagnostic services, Digital healthcare services, and the neuro-rehabilitation business. The Company operates in India, the USA, and other countries, with maximum revenue from the USA.
Contact
Off. Western Express Highway
3rd floor, Kalpataru Inspire
Santacruz East
MumbaiMH400055
INDT: +91 2266402323
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
28,137
Stocks News & Analysis
stocks
ASX utility share downgraded as electricity prices fall
stocks
Chart of the Week: AI market leader is now surprisingly cheap
stocks
Weekly earnings wrap: Rio Tinto leads the way
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,452.00 | 42.10 | 0.45% |
| CAC 40 | 8,699.71 | 30.42 | 0.35% |
| DAX 40 | 26,140.13 | 13.83 | 0.05% |
| Dow JONES (US) | 54,003.97 | 345.15 | -0.64% |
| FTSE 100 | 10,867.89 | 20.41 | -0.19% |
| HKSE | 25,530.28 | 385.54 | -1.49% |
| NASDAQ | 26,357.21 | 6.23 | -0.02% |
| Nikkei 225 | 65,683.26 | 617.18 | -0.93% |
| NZX 50 Index | 13,958.06 | 39.12 | -0.28% |
| S&P 500 | 7,711.21 | 12.34 | -0.16% |
| S&P/ASX 200 | 9,271.60 | 41.80 | 0.45% |
| SSE Composite Index | 3,900.35 | 21.92 | 0.57% |